Financhill
Back

ITeos Therapeutics Quote, Financials, Valuation and Earnings

ITeos Therapeutics Price Quote

$15.11

ITeos Therapeutics Key Stats

Sell
33
ITeos Therapeutics (ITOS) is a Sell

Day range:
$14.88 - $15.95
52-week range:
$12.52 - $28.05
Dividend yield:
0%
P/E ratio:
5.90
P/S ratio:
4.39
P/B ratio:
0.83%

Volume:
342.8K
Avg. volume:
265.9K
1-year change:
-23.42%
Market cap:
$540.4M
Revenue:
$267.6M
EPS:
$0.29

How Much Does ITeos Therapeutics Make?

Is ITeos Therapeutics Growing As A Company?

  • What Is ITeos Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.92%
  • What Is ITeos Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

ITeos Therapeutics Stock Price Performance

What Is ITeos Therapeutics 52-Week High & Low?

ITeos Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy ITeos Therapeutics?

Is ITeos Therapeutics Cash Flow Positive?

  • What Is ITOS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$113.7M
  • What Is ITeos Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $2.2M
  • What Is ITeos Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$477.4M

ITeos Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    ITOS return on invested capital is 1.79%
  • What Is ITeos Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 1.47%
  • What Is ITOS Return On Equity?
    ROE is a measure of profitability and is 1.79%

ITeos Therapeutics Earnings Date & Stock Price

ITeos Therapeutics Competitors

  • Who Are ITeos Therapeutics's Competitors?
    Below is a list of companies who compete with ITeos Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • CEL-SCI Corp (CVM)
    • IGC Pharma Inc (IGC)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Protalix BioTherapeutics Inc (PLX)

ITeos Therapeutics Dividend Yield

Data Unavailable

ITeos Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 786.95%
Revenue: -91.74% 31.72%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 40.12
Upside from Last Price: 165.49%

Major Shareholders

  • How many ITOS shares are owned by institutional investors?
    52.8M ITOS shares are owned by institutional investors
  • How many ITOS shares are owned by insiders?
    134.6K ITOS shares are owned by insiders